Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Bryson

Physician Assistant, Medical Camden, NJ Physician Assistant

NPI 1285972042 CMS profile 10903041

3 Cooper Plz Rm 220, Camden, NJ 08103

Open in the dashboard

General payments

$4,937

332 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Bryson of Camden, NJ is reported in the CMS Open Payments database as having received $4,937 across 332 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $528 32
2024 General $1,286 69
2023 General $1,290 86
2022 General $935 79
2021 General $897 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Bryson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jessica Bryson were reported at $528. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jessica Bryson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $897 $156 $41–$563 $132
2022 $935 $185 $55–$649 $149
2023 $1,290 $199 $58–$717 $160
2024 $1,286 $206 $62–$740 $164
2025 $528 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,786 134 payments
  2. Pfizer Inc. $594 40 payments
  3. Impel Pharmaceuticals Inc. $548 40 payments
  4. Amgen Inc. $374 21 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $282 23 payments
  6. LightForce Orthodontics, Inc. $236 1 payment
  7. Biohaven Pharmaceuticals, Inc. $232 13 payments
  8. Teva Pharmaceuticals USA, Inc. $214 18 payments
  9. Lilly USA, LLC $185 11 payments
  10. Scilex Pharmaceuticals Inc. $172 11 payments
  11. Other $313 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,929 331 payments
  2. Education $8 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $969 72 payments
  2. QULIPTA $816 62 payments
  3. NURTEC ODT Pain $594 40 payments
  4. NURTEC ODT Primary Care $514 36 payments
  5. BOTOX $432 26 payments
  6. AIMOVIG $374 21 payments
  7. Trudhesa Neurology $327 23 payments
  8. ZAVZPRET $276 23 payments
  9. Trudhesa Migraine $222 17 payments
  10. AJOVY $214 18 payments
  11. Other $869 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

2,777

Median for Physician Assistant: 241

Drug cost

$1,125,808

Median for Physician Assistant: $4,110

Branded share of claims

40.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 221 $328,666
Ubrelvy Ubrogepant Brand 193 $272,068
Qulipta Atogepant Brand 159 $178,919
Trudhesa Dihydroergotamine Mesylate Brand 12 $85,490
Aimovig Autoinjector Erenumab-Aooe Brand 80 $65,425
Emgality Pen Galcanezumab-Gnlm Brand 48 $47,461
Zavzpret Zavegepant Hcl Brand 29 $29,871
Ajovy Autoinjector Fremanezumab-Vfrm Brand 36 $26,908
Namzaric Memantine Hcl/Donepezil Hcl Brand 20 $15,132
Trokendi Xr Topiramate Brand 12 $8,589

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$99,472

Of which drugs: $72,453

Medicare patients

182

Average age 67

Services billed

15,285

135 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 52%
Depression 38%
Diabetes 29%
Alzheimer's or dementia 24%
Ischemic heart disease 21%
COPD 17%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 29 14,880 $72,452

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $191
$191 159 —
UBRELVY
  • AbbVie, Inc. $184
$184 193 —
NURTEC ODT
  • PFIZER INC. $166
$166 221 —
BOTOX
  • AbbVie, Inc. $143
$144 — 14,880
ZAVZPRET
  • PFIZER INC. $92
$92 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record